Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2019 / Articles / Jan / Spiraling Towards an Answer
Discovery & Development Vaccines Drug Discovery Research News

Spiraling Towards an Answer

Researchers capture the interactions of antibodies with the parasite responsible for malaria for the first time

By Maryam Mahdi 01/15/2019 0 min read

Share

What begins as a tiny bite from a mosquito, driven by its thirst for blood, can transmit an illness that causes nearly half a million deaths every year: malaria. And though $2.7 billion was spent in an effort to control and eliminate the number of cases of malaria worldwide, risk of transmission remains high, with case incidence steadily rising in the Americas, South-East Asia, Western Pacific and African regions (1).

The battle against malaria has been long and arduous for scientists and healthcare professionals on the front line. The sheer structural complexity of Plasmodium falciparum – the parasite responsible for causing the deadliest form of malaria – makes it a particularly difficult disease to treat.

RTS,S  is a malaria vaccine that has demonstrated protective effects in both children and infants – it received a positive opinion from the European regulatory authorities in July and will be rolled out through a pilot introduction in areas of three African countries beginning in 2019. Scientists at the Scripps Research Institute and PATH’s Malaria Vaccine Initiative have been conducting a cryo-electron microscopy (cryo-EM) investigation, as part of an international effort to further improve the vaccine. Specifically, the researchers looked at antibodies isolated from people who received the RTS,S vaccine and revealed, for the first time, how they interact with P. falciparum by locking the circumsporoite protein on the parasite surface into a spiral-like conformation (2). “We were absolutely delighted to see the first images. No-one could have predicted that we would see a structure like this,” says Ian Wilson, Professor at Scripps Research and co-corresponding author of the study.

“We even remade the sample to validate our results,” adds David Oyen, research fellow at Scripps Research and co-first author of the paper.

Capturing how the human immune system interacts with P. falciparum was previously considered intractable; imaging techniques simply weren’t able to resolve the details.

“Since the CSP contains a multitude of low complexity repeats, different antibodies can bind at the same time, resulting in heterogeneity that is nearly impossible to study and made it crucial for cryo-EM to be used,” says Andrew Ward at Scripps Research, and a corresponding author on the paper.

The team now says it will screen a variety of antibodies from different sources to map the structural features and configurational changes that occur when they bind to circumsporozoite proteins – and hope it will reveal new information about how to block the parasite’s lifecycle in humans. Collaboration with other labs to design new immunogens based on their cryo-EM images is something the team is keen on pursuing. “If we can learn how to focus the immune response on the key structural and functional features of the malaria antigen, we can really make a difference in trying to control this disease,” says Wilson.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. World Health Organization. “Key points: World malaria report 2017.” Available at: https://bit.ly/2zBZdNB Accessed 8 Nov. 2018. D Oyen et al., “Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts,” Science Advances, 4 (2018).

About the Author(s)

Maryam Mahdi

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

More Articles by Maryam Mahdi

False

Advertisement

Recommended

False

Related Content

Understanding the H5N1 Threat
Vaccines Drug Discovery
Understanding the H5N1 Threat

February 3, 2025

4 min read

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Peter Marks Resigns from FDA
Standards & Regulation Profession Vaccines Advanced Medicine
Peter Marks Resigns from FDA

April 1, 2025

3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”

The Shingles Vaccine and Dementia
Drug Discovery Translational Science Vaccines
The Shingles Vaccine and Dementia

April 10, 2025

2 min read

Studies have suggested that the RZV shingles vaccine can lower the risk of dementia; GSK is now investigating further

Robert F. Kennedy Jr Nomination Advances
Standards & Regulation Vaccines
Robert F. Kennedy Jr Nomination Advances

February 6, 2025

2 min read

Senate committee votes in favor of the nomination; full Senate vote will be next

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.